Key facts

Active Substance
Bamlanivimab
Therapeutic area
Infectious diseases
Decision number
P/0221/2021
PIP number
EMEA-002952-PIP01-21
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of Coronavirus disease 2019 (COVID-19)
Route(s) of administration
Intravenous use
Contact for public enquiries

Eli Lilly and Company Limited

E-mail: EU_PAEDIATRIC@LILLY.COM
Tel. +44 (0) 0125631500

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Decision date

Decision

P/0221/2021: EMA decision of 9 June 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for bamlanivimab (EMEA-002952-PIP01-21)

How useful do you find this page?